Switzerland Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	70
ISBN Number	not applicable
Product Code	BMI01644

Price

£425.00
approximately: $835 | €540

PDF immediate delivery

Order above formats by FAX

Summary

Switzerland's drug market is displaying strong growth and should reach a value of US$5.56bn by 2012, driven by demand for innovative pharmaceuticals. Much of the recent growth has been as a result of drugs that have been on the market for less than two years. This reflects the advanced nature of Switzerland's drug market and bodes well for future expansion.

Switzerland's leading pharmaceutical firms Novartis and Roche produced mixed results in 2007, reflecting the current uncertain nature of the global pharmaceutical market. Novartis's total sales reached US$39.8bn, with net income jumping by 66% to US$11.97bn. Yet in the pharmaceuticals division, which is the firm's most important business, operating income fell to US$6.08bn, from US$6.7bn in 2006, due primarily to a poor performance in the US. Roche posted strong results, with sales reaching CHF46.13bn (US$46.26bn), an increase of 10%. Much of this top line growth was as a result of a strong performance in its pharmaceuticals business, where sales grew by 11% to CHF36.8bn (US$36.9bn).

BMI has included Switzerland's medical devices market in its forecasts for the first time. This sector is highly developed and was worth approximately US$1.2bn in 2007. By 2012, the market should reach a value of US$1.5bn, representing a compound annual growth rate (CAGR) of around 5%, which is roughly in line with growth in the pharmaceutical market. Like Switzerland's drug sector, the medical devices industry is characterised by impressive technological standards and a high density of operators.

Switzerland retains its position in BMI's Business Environment Ranking for the Western Europe region and remains in second place in global terms. The country's regulatory structures are superb, while percapita drug expenditure is high. The country's strong economy and stable political environment is highly beneficial.

Content

Executive Summary
Switzerland Pharmaceuticals And Healthcare Industry SWOT
Switzerland Political SWOT
Switzerland Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe Pharmaceutical Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Switzerland - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
- Table: A Comparison Of Medicine Prices In Western Eur
Industry Developments
Healthcare Sector
Pharmaceutical Sector
Domestic Industry
Multinational Sector
Roche Boosted By Biotechnology
Novartis Announces Restructuring
Research And Development Sector
Hospital Sector
Biotechnology Sector
Industry Forecast Sce34
Overall Market Forecast
- Table: Swiss Pharmaceutical Expenditure Indicators, 2006-2012
Key Growth Factors - Industry
- Table: Swiss Health Expenditure Indicators, 2006-2012
Key Growth Factors - Macroeconomic
- Table: Switzerland - Economic Forecasts
Branded Forecasts
- Table: Swiss Patented Pharmaceutical Market Indicators, 2005-2012
OTC Market Forecast
- Table: Swiss OTC Market Indicators, 2006-2012 (US$mn unless otherwise stated)
Generics Market Forecasts
- Table: Swiss Generics And Branded Market Indicators, 2006-2012
Export/Import Forecasts
- Table: Swiss Pharmaceuticals Exports And Imports Indicators, 2006-2012 (US$mn)
Medical Devices
- Table: Switzerland Medical Device Market Indicators, 2006-2012 (US$bn unless otherwise stated)
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Pfizer
Sanofi-Aventis
Merck & Co
Indigenous Manufacturers
Novartis
Roche
Serono (Merck-Serono)
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
Weighting
- Table: Weighting Of Components
Sources